Ernexa Therapeutics Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

ERNA$2.01-2.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

For the three months ended March 31, 2026 and 2025 (unaudited)

(In thousands)

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at January 1, 2026	156	$1	314	$2	$248,034	$(245,636)	$2,401
Issuance of common stock, prefunded warrants and warrants
in connection with public offering, net	-	-	769	4	9,537	-	9,541
Issuance of common stock from the exercise of prefunded
warrants, net	-	-	80	-	18	-	18
Issuance of common stock to consultant for services	-	-	3	-	96	-	96
Stock-based compensation	-	-	-	-	309	-	309
Net loss	-	-	-	-	-	(5,506)	(5,506)
Balances at March 31, 2026	156	$1	1,166	$6	$257,994	$(251,142)	$6,859

Series A Preferred Stock · Common Stock · Additional Paid-in · Accumulated
	Shares	Amount	Shares	Amount	Capital	Deficit	Total
Balances at January 1, 2025	156	$1	137	$1	$233,219	$(231,536)	$1,701
Issuance of common stock from the exercise
of prefunded warrants	-	-	2	-	4	-	4
Issuance of common stock to consultant for services	-	-	-	-	45	-	45
Stock-based compensation	-	-	-	-	502	-	502
Net loss	-	-	-	-	-	(8,202)	(8,202)
Balances at March 31, 2025	156	$1	139	$1	$233,770	$(239,738)	$(5,950)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.